Fulvestrant Injection

Fulvestrant injection, an injection for intramuscular administration,
is supplied as 250 mg/5 mL fulvestrant.
It is an an estrogen receptor antagonist indicated
for the treatment of:
· Hormone receptor (HR)-positive advanced breast cancer in
postmenopausal women with disease progression following
endocrine therapy. (1)
· HR-positive, HER2-negative advanced or metastatic breast
cancer in postmenopausal women in combination with
ribociclib, as initial endocrine based therapy or following
disease progression on endocrine therapy. (1)
· HR-positive, HER2-negative advanced or metastatic breast
cancer in combination with palbociclib or abemaciclib in
women with disease progression after endocrine therapy